Pre-clinical studies with tumor suppressor genes

Advances in Experimental Medicine and Biology

Volumn 465, Issue , 2000, Pages 183-192

  Seth, P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR; NEOMYCIN; PLASMID DNA; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; APOPTOSIS; CANCER GROWTH; CANCER THERAPY; CELL CYCLE; GENE THERAPY; GENE TRANSFER; GROWTH INHIBITION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; FORECASTING; GENES, P53; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; RESEARCH;

ADENOVIRIDAE; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0034475167     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (52)

1. Suppression of human colorectal carcinoma cell growth by wild-type p53
2. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer
3. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene
4. Suppression of growth of renal carcinoma cells by the yon Hippel-Lindau tumor suppressor gene
5. Genetic mechanisms of tumor suppression by the human p53 gene
6. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer
7. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
8. Consequences of adenoviral-mediated p16 protein expression on cell cycle arrest are determined by the endogenous Rb and p16 status in human breast cancer cells
9. Recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells
10. A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth
11. Preliminary report: The short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas
12. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival
13. Role of wild-type-53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells
14. Tumour suppression by the human yon Hippel-Lindau gene product
15. The VHL turnout-suppressor gene paradigm
16. Cytotoxic effects of a recombinant adenovirus expressing human wild type p53 on tumor and normal mammary epithelial cells
17. Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis
18. Promoting apoptosis: A novel activity associated with cyclin-dependent kinase inhibitor p27/Kip1
19. A recombinant adenovirus expressing tumor suppressor gene VHL induces cell cycle arrest by upregulating cyclin-dependent kinase inhibitor p27Kip1
20. p53: Puzzle and paraqdigm
21. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition
22. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
23. Efficacy of multiple administrations of a recombinant adenovirus expressing wild type p53 in an immune-competent mouse tumor model
24. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
25. Apoptosis and APC in colorectal tumorigenesis
26. Mutations in the p53 gene occur in diverse human tumour types
27. A phase 1 trial of retroviral BRCA1sv gene therapy in ovarian cancer
28. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
29. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53
30. Adenoviral expression of the cyclin-dependent kinase inhibitor p27/Kip1: A stategy for breast cancer gene therapy
31. p53 mediated apoptosis is associated with up-regulation of Fas/CD95/Apo-1
32. Bystander effect in the context of Ad.p53 virus
33. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer
34. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
35. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
36. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
37. Recombinant adenoviral vector expressing p53 for cancer gene therapy
38. A recombinant adenovirus expressing wild type p53 induces apoptosis in drug resistant breast cancer cells: A gene therapy approach for drug reistant cancers
39. Cancer gene therapy with adenoviral vectors expressing tumor suppressor genes
40. Vectors for cancer gene therapy
41. Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging
42. Induction of apoptosis by the tumor suppressor protein BRCA1
43. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line
44. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAFI/CiP1
45. Role of p53 and apoptosis in sensitization of cis-diaminedoichloroplatinum antitumor activity by interleukin-1α in ovarian carcinoma cells
46. Chemosensitization of ovarian carcinomas by wild type p53 gene transfer by adenovirus vector
47. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer
48. Complex structure and regulation of the P16 (MTS1) locus
49. Association of the APC tumor suppressor protein with catenins
50. The retinoblastoma gene and gene product
51. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein
52. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity